NCT01069510View on ClinicalTrials.gov

Spironolactone in Adult Congenital Heart Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

June 30, 2016

Study Completion Date

March 31, 2017

Conditions
Congenital Heart DiseaseHeart FailureEndomyocardial Fibrosis
Interventions
DRUG

Spironolactone 25mg

Spironolactone 25 mg daily for 12 months

OTHER

Placebo

Placebo daily for 12 months

Trial Locations (1)

97239

Oregon Health & Science University, Portland

Sponsors
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Oregon Clinical and Translational Research Institute

OTHER

lead

Oregon Health and Science University

OTHER